Mar 06, 2024 7:30am EST Rezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH)
Feb 13, 2024 4:05pm EST Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update
Jan 24, 2024 8:00am EST Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial Officer
Jan 23, 2024 8:00am EST Rezolute Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism
Dec 14, 2023 8:00am EST Rezolute Initiates Phase 3 Clinical Study for RZ358 in Congenital Hyperinsulinism
Dec 13, 2023 8:00am EST Rezolute Completes Enrollment of its Phase 2 Study in Diabetic Macular Edema (“DME”)
Oct 17, 2023 8:00am EDT Rezolute Receives Priority Medicines (PRIME) Eligibility from European Medicines Agency for Enhanced Regulatory Support of RZ358 in Congenital Hyperinsulinism
Oct 11, 2023 8:00am EDT Rezolute Announces Further Evidence of RZ358’s Efficacy in Tumor-Mediated Hyperinsulinism